表紙
市場調查報告書
商品編碼
1060129

生技藥品的全球市場:預測(2021年∼2026年)

Biologics Market - Forecasts from 2021 to 2026

出版日期: | 出版商: Knowledge Sourcing Intelligence | 英文 121 Pages | 商品交期: 最快1-2個工作天內

價格
  • 全貌
  • 簡介
  • 目錄
簡介

全球生技藥品的市場規模,從2019年的2,699億3,100萬美元,預計到2026年達到4,833億9,300萬美元,以8.68%的年複合成長率發展。

由於重要的市場參與者的資金投資擴大,慢性病患的負擔增加,主要的生物製藥的專利獨佔權的喪失,及對新治療的需求與接受性的高漲,都牽引該產業。根據2018年的世界衛生組織的統計,每年有4,100萬人以上因慢性疾病死亡。還有增加的老年人世代對慢性疾病更脆弱,這個成為生技藥品的需求增加的原因之一。

本報告提供全球生技藥品市場相關調查分析,市場動態,市場分析,競爭資訊,企業簡介等系統性資訊。

目錄

第1章 簡介

  • 市場概要
  • COVID-19情境
  • 市場定義
  • 市場區隔

第2章 調查手法

  • 調查資料
  • 前提條件

第3章 摘要整理

  • 調查的重點

第4章 市場動態

  • 市場促進因素
  • 市場阻礙因素
  • 波特的五力分析
    • 終端用戶談判力
    • 買方議價能力
    • 新加入業者的威脅
    • 替代品的威脅
    • 產業的競爭企業間的敵對關係
  • 產業的價值鏈分析

第5章 全球生技藥品市場分析:各產品類型

  • 簡介
  • 單株抗體
  • 疫苗
  • 重組蛋白質
  • 基因治療
  • 細胞為基礎的生技藥品
  • 其他

第6章 全球生技藥品市場分析:各用途

  • 簡介
  • 腫瘤學
  • 神經學
  • 心臟病
  • 血液學
  • 自體免疫疾病
  • 感染疾病
  • 其他

第7章 全球生技藥品市場分析:各地區

  • 簡介
  • 北美
    • 美國
    • 加拿大
    • 墨西哥
  • 南美
    • 巴西
    • 阿根廷
    • 其他
  • 歐洲
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他
  • 中東、非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 南非
    • 其他
  • 亞太地區
    • 中國
    • 印度
    • 日本
    • 韓國
    • 台灣
    • 泰國
    • 印尼
    • 其他

第8章 競爭環境與分析

  • 主要企業策略分析
  • 新興企業與市場的有利性
  • 合併,收購,協定,及合作
  • 供應商競爭矩陣

第9章 企業簡介

  • F. Hoffmann-La Roche AG
  • Amgen Inc.
  • AbbVie Inc.
  • Novo Nordisk A/S
  • Johnson & Johnson
  • Takeda Pharmaceutical Company
  • Alexion Pharmaceuticals
  • Samsung Biologics
  • UCB S.A.
  • Merck & Co. Inc
  • Eli Lilly and Company
  • Sanofi SA
目錄
Product Code: KSI061611837

The global biologics market is projected to grow at a CAGR of 8.68% to reach US$483.393 billion by 2026, from US$269.931 billion in 2019. Biologics are medicines that are made up of genetically modified proteins obtained from human DNA. Biologics can be made up of carbohydrates, proteins, nucleic acids, or complex mixtures of these chemicals, or living things like cells and tissues, according to the US FDA. The majority of biologics are complex mixes that are difficult to describe or identify, are heat sensitive, and are prone to microbial contamination. Biologic products come from a wide range of natural sources, including animals, people, and microbes. Biologics are made using modern biotechnology techniques and complicated procedures. During the COVID-19 pandemic, there had been a large need for biologics because of the rising COVID-19 load, which may fuel market expansion. For example, the National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 on the clinical development of a COVID-19 vaccine in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is now in Phase II development in Wuhan, China. As a result, the biologics market is projected to increase in the near future due to substantial research and development activity on biologics for the treatment of COVID-19.

Growing financial investment from important market participants, an increase in the burden of chronic illnesses, the loss of patent exclusivity for top biologic medicines, and rising demand and acceptability for novel therapies are all driving the industry. Vaccines, blood and blood components, allergenic, somatic cells, gene therapy, tissues, and recombinant therapeutic proteins are examples of biologics. The majority of biologics are complex mixes that are difficult to identify or describe, are heat sensitive, and are prone to microbial contamination. In the year 2018, due to increased demand for Merck's medicines and vaccines, the firm recently announced the construction of a second production unit for vaccines and biologics in Ireland. Chronic illnesses kill more than 41 million people each year, according to World Health Organization figures from 2018. The most common chronic disease, cardiovascular disease, kills 17.9 million people per year, followed by cancer (9.3 million), respiratory disorders (4.1 million), and diabetes (1.5 million). Eighty percent of all chronic disease fatalities are caused by these four categories. Non-communicable illnesses are caused by tobacco use, physical inactivity, alcohol use, and poor diets. Furthermore, the growing elderly population is more vulnerable to chronic illnesses, which contributes to an increase in biologics demand.

Growth Factors

Technological advancements and robust research and development will lead to market growth.

One of the major reasons for the growth of the global biologics market is the increasing technological advancements and robust research and development. These research and development efforts have resulted in higher success rates in biologics clinical trials. Market leaders in the biologics market do research and development as they try to achieve breakthroughs in the market in the form of new and effective biologics. Biocon Limited, for example, is working on tregopil, oral prandial insulin for the treatment of type 2 diabetes that is now in phase II/III clinical studies. Insulin tregopil is now being studied in Phase II/III clinical trials for Type 2 diabetic patients. Oramed Pharmaceuticals, located in Jerusalem, developed ORMD-0801, an oral insulin medication now in phase 2 studies to treat type 2 diabetes. The US Food and Medication Administration gave Novo Nordisk, a Danish multinational pharmaceutical firm, clearance to market its Rybelsus oral diabetic drug in September 2019. Rybelsus is an oral version of semaglutide that is used to treat type 2 diabetic patients. These advancements in technology have boosted the market growth of the global biologics market during the forecast period.

Restraints

  • Market restraints might be imposed by strict regulatory criteria for biologics approval.

A major restraint in the growth of the global biologics market is the stringent regulatory requirements for biologics approval. In the projected term, the biologics market is expected to be hampered by strict rules placed on biologics approvals. The manufacture and use of biologics are governed by various regulations in different areas. Furthermore, difficulties such as patent infringement or contract concerns prevent biologics producers from commercializing government-approved biosimilars. These factors continue to hamper the growth of the global biologics market during the forecast period.

Impact of COVID-19 on the Biologics Market

The COVID-19 impact on the global biologics market has been positive owing to the rise in the demand for biologics during the COVID-19 pandemic. The rising technological advancements and the growing research and development to develop vaccines for the virus have been extensive resulting in the increasing demand for biologics. With the increasing COVID-19 pandemic, businesses in the United States are rushing to produce COVID-19 vaccinations. For example, in March 2020, Kaiser Permanente Washington Health Research Institute (KPWHRI) in Seattle launched a Phase 1 clinical trial to investigate an experimental vaccination designed to protect against COVID-19. Scientists from the National Institute of Allergy and Infectious Diseases and its partners at the biotechnology firm Moderna Inc. are working on the vaccine. Also, the National Research Council of Canada and CanSino Biologics, located in China, partnered in May 2020 to develop a COVID-19 vaccine in Canada. Ad5-nCoV is an adenovirus Type 5 vector-based vaccination that is now in Phase II development in Wuhan, China. The surging demand for biologics during the course of the pandemic has fueled the market growth of the global biologics market.

Competitive Insights

The market leaders in the pretreatment coating market are F. Hoffmann-La Roche AG, Amgen Inc., AbbVie Inc., Novo Nordisk A/S, Johnson & Johnson, Takeda Pharmaceutical Company, Alexion Pharmaceuticals, Samsung Biologics, UCB S.A., Merck & Co. Inc, Eli Lilly, and Company, Sanofi SA

Segmentation:

  • By Type

Monoclonal Antibodies

Vaccines

Recombinant Proteins

Gene Therapy

Others

  • By Application

Oncology

Neurology

Orphan Indications

Infectious Diseases

Others

  • By Geography

North America

  • USA
  • Canada
  • Mexico

South America

  • Brazil
  • Argentina
  • Others

Europe

  • UK
  • Germany
  • France
  • Spain
  • Others

Middle East and Africa

  • Saudi Arabia
  • Israel
  • Others

Asia Pacific

  • Japan
  • China
  • India
  • Indonesia
  • Taiwan
  • Thailand
  • Others

Table of Contents

1. Introduction

  • 1.1. Market Overview
  • 1.2. Covid-19 Scenario
  • 1.3. Market Definition
  • 1.4. Market Segmentation

2. Research Methodology

  • 2.1. Research Data
  • 2.2. Assumptions

3. Executive Summary

  • 3.1. Research Highlights

4. Market Dynamics

  • 4.1. Market Drivers
  • 4.2. Market Restraints
  • 4.3. Porter's Five Forces Analysis
    • 4.3.1. Bargaining Power of End-Users
    • 4.3.2. Bargaining Power of Buyers
    • 4.3.3. Threat of New Entrants
    • 4.3.4. Threat of Substitutes
    • 4.3.5. Competitive Rivalry in the Industry
  • 4.4. Industry Value Chain Analysis

5. Global Biologics Market Analysis, by Product Type

  • 5.1. Introduction
  • 5.2. Monoclonal Antibodies
  • 5.3. Vaccines
  • 5.4. Recombinant Proteins
  • 5.5. Gene Therapy
  • 5.6. Cellular-based Biologics
  • 5.7. Others

6. Global Biologics Market Analysis, by Application

  • 6.1. Introduction
  • 6.2. Oncology
  • 6.3. Neurology
  • 6.4. Cardiology
  • 6.5. Hematology
  • 6.6. Autoimmune Diseases
  • 6.7. Infectious Diseases
  • 6.8. Others

7. Global Biologics Market Analysis, by Geography

  • 7.1. Introduction
  • 7.2. North America
    • 7.2.1. USA
    • 7.2.2. Canada
    • 7.2.3. Mexico
  • 7.3. South America
    • 7.3.1. Brazil
    • 7.3.2. Argentina
    • 7.3.3. Others
  • 7.4. Europe
    • 7.4.1. Germany
    • 7.4.2. France
    • 7.4.3. UK
    • 7.4.4. Italy
    • 7.4.5. Spain
    • 7.4.6. Others
  • 7.5. Middle East and Africa
    • 7.5.1. Saudi Arabia
    • 7.5.2. UAE
    • 7.5.3. South Africa
    • 7.5.4. Others
  • 7.6. Asia Pacific
    • 7.6.1. China
    • 7.6.2. India
    • 7.6.3. Japan
    • 7.6.4. South Korea
    • 7.6.5. Taiwan
    • 7.6.6. Thailand
    • 7.6.7. Indonesia
    • 7.6.8. Others

8. Competitive Environment and Analysis

  • 8.1. Major Players and Strategy Analysis
  • 8.2. Emerging Players and Market Lucrativeness
  • 8.3. Mergers, Acquisitions, Agreements, and Collaborations
  • 8.4. Vendor Competitiveness Matrix

9. Company Profiles 

  • 9.1. F. Hoffmann-La Roche AG
  • 9.2. Amgen Inc.
  • 9.3. AbbVie Inc.
  • 9.4. Novo Nordisk A/S
  • 9.5. Johnson & Johnson
  • 9.6. Takeda Pharmaceutical Company
  • 9.7. Alexion Pharmaceuticals
  • 9.8. Samsung Biologics
  • 9.9. UCB S.A.
  • 9.10. Merck & Co. Inc
  • 9.11. Eli Lilly and Company
  • 9.12. Sanofi SA